| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Jul 17, 2026 | Option/RSU Exercise | $2.48 | 5,000 | 12,400 | 30,000 | Jul 21, 2026, 05:23 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale | $52.67 | 5,000 | 263,373 | 29,769 | Jul 21, 2026, 05:23 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Jun 17, 2026 | Option/RSU Exercise | $2.48 | 5,000 | 12,400 | 30,000 | Jun 22, 2026, 05:11 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale | $43.80 | 5,000 | 219,017 | 28,732 | Jun 22, 2026, 05:11 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | May 18, 2026 | Sale | $39.79 | 5,000 | 198,971 | 26,525 | May 20, 2026, 04:18 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | May 18, 2026 | Option/RSU Exercise | $2.48 | 5,000 | 12,400 | 30,000 | May 20, 2026, 04:18 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Apr 17, 2026 | Option/RSU Exercise | $2.48 | 5,000 | 12,400 | 30,000 | Apr 21, 2026, 08:40 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale | $47.67 | 5,000 | 238,352 | 29,860 | Apr 21, 2026, 08:40 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 25, 2026 | Option/RSU Exercise | $2.48 | 40,000 | 99,200 | 65,000 | Mar 27, 2026, 04:57 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 25, 2026 | Sale | $35.10 | 40,000 | 1,404,024 | 25,000 | Mar 27, 2026, 04:57 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale | $27.76 | 5,000 | 138,800 | 25,000 | Mar 19, 2026, 05:50 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 17, 2026 | Option/RSU Exercise | $2.48 | 5,000 | 12,400 | 30,000 | Mar 19, 2026, 05:50 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 09, 2026 | Option/RSU Exercise | $2.48 | 29,871 | 74,080 | 54,871 | Mar 11, 2026, 05:32 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 09, 2026 | Sale | $30.02 | 29,871 | 896,811 | 25,000 | Mar 11, 2026, 05:32 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 10, 2026 | Option/RSU Exercise | $2.48 | 10,129 | 25,120 | 35,129 | Mar 11, 2026, 05:32 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 10, 2026 | Sale | $30.19 | 10,129 | 305,827 | 25,000 | Mar 11, 2026, 05:32 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Option/RSU Exercise | $2.48 | 45,000 | 111,600 | 70,000 | Feb 19, 2026, 06:36 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sale | $26.17 | 45,000 | 1,177,861 | 25,000 | Feb 19, 2026, 06:36 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Oct 18, 2024 | Option/RSU Exercise | $2.48 | 816 | 2,024 | 816 | Oct 22, 2024, 04:17 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Oct 18, 2024 | Sale | $30.00 | 816 | 24,482 | 0 | Oct 22, 2024, 04:17 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Apr 11, 2024 | Sale | $25.07 | 20,000 | 501,478 | 0 | Apr 15, 2024, 07:02 PM | |
| ELVN | Enliven Therapeutics, Inc. | Helen Louise Collins | CHIEF MEDICAL OFFICER | Apr 11, 2024 | Option/RSU Exercise | $2.48 | 20,000 | 49,600 | 20,000 | Apr 15, 2024, 07:02 PM |
- Subscribe
- Premium
- C-Suite
- Insiders
- M&A
- Gurus
- Spinoffs
- Buybacks
- More